ArticleBritish journal of cancer2026
Stage I non-small cell lung cancer: improving patient selection for minimally invasive lobectomy or stereotactic ablative radiotherapy based on clinical characteristics.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundWe aimed to identify patient and tumour characteristics associated with differential benefit from minimally invasive lobectomy (MIL) or stereotactic ablative radiotherapy (SABR) for stage I non-small cell lung cancer (NSCLC).
methodsPatients with clinical stage I NSCLC (TNM7), treated with MIL or SABR in 2014-2016, were included in this retrospective cohort study. Propensity score (PS) weighting was used to create a virtual SABR cohort with characteristics comparable to the MIL group. We assessed interactions between treatment type and clinical characteristics affecting overall survival (OS) and recurrence-free survival (RFS).
results1211 MIL and 972 SABR patients were included. After PS weighting, the impact of treatment type on OS differed significantly between patients with prior myocardial infarction or heart failure (HR 0.51, 95% CI 0.32-0.82; favouring MIL) versus patients without (HR 1.09, 95% CI 0.70-1.67) (p = 0.02). Moreover, MIL yielded superior OS in patients with both FEV
conclusionsInteractions of treatment type with lung function and with prior myocardial infarction or heart failure impacted OS for patients with stage I NSCLC. These findings warrant validation in other studies to further refine treatment decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.